Sanofi Pasteur’s controversial vaccine dengvaxia has been approved by the US Food & Drug Administration, the first dengue vaccine to get the regulatory nod in the US.
About:
What is it? Dengvaxia is a live, attenuated dengue virus. An attenuated virus is a virus that retains its properties of triggering an immune response in the body but its ability to lead to a disease is compromised.
Technical name: CYD-TDV.
Features: CYD-TDV is a live recombinant tetravalent dengue vaccine developed by Sanofi Pasteur (CYD-TDV), given as a 3-dose series on a 0/6/12 month schedule.
Global scenario:
Dengvaxia is the first dengue vaccine to be licensed, Mexico being the first country to clear it in 2015. Subsequently it has been cleared in some 20 countries.
But Dengvaxia ran into trouble in 2017 when the Philippines had to suspend a school vaccination programme following several casualties.
In this background, the United States FDA has now cleared it for use only in people who have a previous history of the disease, particularly in dengue-endemic areas.
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
